Healthy Adults With Mild Cognitive Impairment (MCI) and a 16-week Intervention With Mitocholine™, a Functional Food Ingredient

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-09

Study Completion Date

2024-09-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effect of 16-weeks consumption of Mitocholine on Executive Function and Homocysteine levels in a population experiencing Mild Cognitive Impairment. The study will also include measures of memory, language, S-adenosylmethionone (SAM), Betaine, Choline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)

NCT00567060

Memory Disorders

COMPLETED NA

Effects of Mitochondrial-targeted Antioxidant on Mild Cognitive Impairment (MCI) Patients

NCT03514875

Alzheimer Disease, Early Onset Mild Cognitive Impairment

WITHDRAWN NA

Efficacy of MEMORMAX in Subjects With MCI

NCT03581929

Mild Cognitive Impairment

COMPLETED NA

Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints

NCT00597376

Subjective Memory Loss in Older Persons

COMPLETED NA

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)

NCT06347315

Mild Cognitive Impairment

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomised, double-blinded, placebo-controlled, parallel proof of concept study

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mitocholine™

Mitocholine™ is a novel formulation of three nutrients choline, succinic acid, and nicotinamide (a vitamin B3)

Group Type EXPERIMENTAL

Mitocholine™ or Placebo

Intervention Type DIETARY_SUPPLEMENT

Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.

Placebo

The Placebo product will be identical in appearance and taste to the investigational product

Group Type PLACEBO_COMPARATOR

Mitocholine™ or Placebo

Intervention Type DIETARY_SUPPLEMENT

Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mitocholine™ or Placebo

Participants will be instructed to consume one bottle of study product daily for the duration of the trial (16 weeks). They will be instructed to consume the product in the morning with breakfast.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Willing to participate in the study and comply with its procedures.
2. Able to give written informed consent.
3. Adults aged 55 to 79 years, inclusive.
4. Meet MCI criteria, based on the Peterson criteria (Peterson et al., 1999):

1. Objective evidence of cognitive impairment as assessed by MoCA (score ≥18 to ≤25).
2. Absence of major depression as assessed by PHQ (score \<10).
3. Activities of daily living score

* males ≥4
* females ≥7
5. Have a homocysteine level ≥11.0μmol/L (Smith D et al, 2018).

Exclusion Criteria

1. Diagnosis of a major cognitive disorder (e.g. Alzheimer's or Parkinson's disease diagnoses; additionally, confirmation of a mini stroke (TIA) within the last 3 months would be an exclusionary condition).
2. Participants who are pregnant or wish to become pregnant during the trial.
3. Participants who are lactating and/or currently breastfeeding.
4. Participants currently of childbearing potential, but not using an effective method of contraception, as determined by the investigator.
5. Participants with active or a history of alcohol or substance abuse; (exclude elevated Gamma GT \& clinically abnormal liver function test).
6. Uncontrolled diabetes (or glycated haemoglobin \>7% / 53 mmol/mol).
7. Clinically significant heart, liver, or renal disease (at the discretion of the investigator).
8. Have uncontrolled hypertension SBP \> 160mmHg, DBP \> 100mmHg).
9. Participants prescribed medications likely to influence memory or mood, as determined by the investigator.
10. Participants with a history of depression (within past 24 months) or any concurrent medical, cognitive or psychiatric condition that would either: compromise his/her ability to comply with the study requirements, may pose significant risk to the participant, or be deemed exclusionary by the investigator
11. Have had any other condition or are taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk, or confound the interpretation of the study results.
12. Change in supplements, medication, or major diet in 30 days prior to enrolment and throughout the study.
13. Taking any supplements or vitamins notably known to affect cognitive function (e.g. Living Nutrition Cognitive, Viridian Cognitive Complex, ginkgo biloba, fish oil etc., list not exhaustive), or any psychotropic medications and products which interact with acetylcholine esterase and/or NMDA receptors (6-week washout before screening). Vitamin D and Calcium supplements permitted if on a stable dose for the previous 3 months.
14. Users of inhaled nicotine products such as cigarettes or vape products with an inconsistent recent history of consumption i.e., those who have taken up smoking/vaping in the 12 months prior to screening, or those who have either given up or re-started smoking or vaping in the 12 months prior to screening, or those who intend to significantly modify their use of inhaled nicotine products during their participation in the study.
15. Has received treatment involving experimental drugs in the past 3 months.
16. Have a malignant disease or any concomitant end-stage organ disease, which, in the Investigator's judgment, contraindicates participation in the study.
17. Individuals who, in the opinion of the investigator, are considered to be poor clinical attendees or unlikely for any reason to be able to comply with the trial.
18. Any Participant who is an employee of the study site or an Atlantia Clinical Trials employee or their close family member or a member of their household.

Minimum Eligible Age

55 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes